263 related articles for article (PubMed ID: 32448839)
21. Immunotherapy rechallenge in patients with non-small-cell lung cancer.
España S; Guasch I; Carcereny E
Pulmonology; 2020; 26(4):252-254. PubMed ID: 32354686
[No Abstract] [Full Text] [Related]
22. Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab.
Pantano F; Russano M; Berruti A; Mansueto G; Migliorino MR; Adamo V; Aprile G; Gelibter A; Ficorella C; Falcone A; Russo A; Aieta M; Maio M; Martelli O; Barni S; Napolitano A; Roca E; Quadrini S; Iacono D; Russo A; Calvetti L; Occhipinti MA; Cortellini A; Vasile E; Passiglia F; Imperatori M; Calabrò L; Di Giacomo AM; Petrelli F; Pasquini G; Franchina T; Venditti O; Intagliata S; Galvano A; Fioroni I; Vincenzi B; Tonini G; Santini D
Expert Opin Biol Ther; 2020 Mar; 20(3):319-326. PubMed ID: 32011207
[No Abstract] [Full Text] [Related]
23. Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab.
Bukamur H; Katz H; Alsharedi M; Alkrekshi A; Shweihat YR; Munn NJ
South Med J; 2020 Nov; 113(11):600-605. PubMed ID: 33140115
[TBL] [Abstract][Full Text] [Related]
24. Perimyocarditis Associated with Immune Checkpoint Inhibitors: A Case Report and Review of the Literature.
Shalata W; Steckbeck R; Abu Salman A; Abu Saleh O; Abu Jama A; Attal ZG; Shalata S; Alnsasra H; Yakobson A
Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399513
[TBL] [Abstract][Full Text] [Related]
25. Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals.
Tournoy KG; Thomeer M; Germonpré P; Derijcke S; De Pauw R; Galdermans D; Govaert K; Govaerts E; Schildermans R; Declercq I; De Brucker N; Pat K; Van Herreweghe R; Van Zandweghe L; Vanmaele L; Van Damme V; Marien H; De Craene S; Fabry I; Alexander P; Vercauter P; Demedts I
Lung Cancer; 2018 Jan; 115():49-55. PubMed ID: 29290261
[TBL] [Abstract][Full Text] [Related]
26. [Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC].
El-Ghazzi N; Lavaud P
Bull Cancer; 2021 Mar; 108(3):231-233. PubMed ID: 33622569
[No Abstract] [Full Text] [Related]
27. Palmoplantar Pustulosis Caused by Immune-Checkpoint Inhibitors.
Furuta H; Kato S; Masago K; Hida T
Clin Lung Cancer; 2021 Nov; 22(6):e829-e832. PubMed ID: 34023207
[No Abstract] [Full Text] [Related]
28. Goodpasture's disease in a patient with advanced lung cancer treated with nivolumab: An autopsy case report.
Takahashi N; Tsuji K; Tamiya H; Shinohara T; Kuroda N; Takeuchi E
Lung Cancer; 2018 Aug; 122():22-24. PubMed ID: 30032835
[TBL] [Abstract][Full Text] [Related]
29. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.
Vokes EE; Ready N; Felip E; Horn L; Burgio MA; Antonia SJ; Arén Frontera O; Gettinger S; Holgado E; Spigel D; Waterhouse D; Domine M; Garassino M; Chow LQM; Blumenschein G; Barlesi F; Coudert B; Gainor J; Arrieta O; Brahmer J; Butts C; Steins M; Geese WJ; Li A; Healey D; Crinò L
Ann Oncol; 2018 Apr; 29(4):959-965. PubMed ID: 29408986
[TBL] [Abstract][Full Text] [Related]
30. Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report.
Sakoh T; Kanzaki M; Miyamoto A; Mochizuki S; Kakumoto T; Sato K; Uesaka Y; Kishi K
BMC Cancer; 2019 Dec; 19(1):1220. PubMed ID: 31842803
[TBL] [Abstract][Full Text] [Related]
31. Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.
Yotsukura M; Nakagawa K; Suzuki K; Takamochi K; Ito H; Okami J; Aokage K; Shiono S; Yoshioka H; Aoki T; Tsutani Y; Okada M; Watanabe SI;
Jpn J Clin Oncol; 2021 Jan; 51(1):28-36. PubMed ID: 33147608
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy-Induced Airway Disease: A New Pattern of Lung Toxicity of Immune Checkpoint Inhibitors.
Mitropoulou G; Daccord C; Sauty A; Pasche A; Egger B; Aedo Lopez V; Letovanec I; Beigelman-Aubry C; Nicod LP; Lazor R
Respiration; 2020; 99(2):181-186. PubMed ID: 31914436
[TBL] [Abstract][Full Text] [Related]
33. Nivolumab-induced seronegative encephalitis.
Cabral G; Ladeira F; Gil N
J Neuroimmunol; 2020 Oct; 347():577350. PubMed ID: 32768895
[TBL] [Abstract][Full Text] [Related]
34. Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease.
Leaver PJ; Jang HS; Vernon ST; Fernando SL
BMJ Case Rep; 2020 May; 13(5):. PubMed ID: 32404371
[TBL] [Abstract][Full Text] [Related]
35. Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.
Sarocchi M; Grossi F; Arboscello E; Bellodi A; Genova C; Dal Bello MG; Rijavec E; Barletta G; Rossi G; Biello F; Ghigliotti G; Canepa M; Mussap M; Brunelli C; Spallarossa P
Oncologist; 2018 Aug; 23(8):936-942. PubMed ID: 29567824
[TBL] [Abstract][Full Text] [Related]
36. Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up.
McClure T; Cui W; Asadi K; John T; Testro A
BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32912846
[TBL] [Abstract][Full Text] [Related]
37. Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer.
de Jong C; Peters BJM; Schramel FMNH
Chemotherapy; 2018; 63(5):272-277. PubMed ID: 30572331
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer.
Tamura N; Horinouchi H; Sekine K; Matsumoto Y; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Ohe Y
Thorac Cancer; 2019 May; 10(5):1141-1148. PubMed ID: 30913364
[TBL] [Abstract][Full Text] [Related]
39. [A case of severe colitis caused by immune checkpoint inhibitor].
Kanamori H; Yasuhara H; Mashima S; Suto K; Yamauchi K; Akita M; Jinno H; Hata H; Nakatsu M; Ando M
Nihon Shokakibyo Gakkai Zasshi; 2019; 116(3):235-240. PubMed ID: 30853676
[TBL] [Abstract][Full Text] [Related]
40. A Case of Severe Acute Gastritis as an Immune-Related Adverse Event After Nivolumab Treatment: Endoscopic and Pathological Findings in Nivolumab-Related Gastritis.
Ebisutani N; Tozawa K; Matsuda I; Nakamura K; Tamura A; Hara K; Kondo T; Terada T; Tomita T; Oshima T; Fukui H; Hirota S; Miwa H
Dig Dis Sci; 2021 Jul; 66(7):2461-2465. PubMed ID: 32780186
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
